APOM and polycystic ovary syndrome: Modeling the predicted changes as a response to increasing BMI, IR and inflammation suggests the following: a significantly increase in C3, with a decrease in heparin cofactor-II, apoM and alpha-1-antichymotrypsin; however, these changes may only be seen in women with PCOS and not in obese control women, indicating an increased cardiovascular risk for obese women with PCOS.